Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zocor Exclusivity: Ranbaxy Needs Quick Win In Suit Seeking Patent Re-Listing

Executive Summary

Ranbaxy needs a relatively quick win in its lawsuit against FDA if it hopes to benefit from the 180-day exclusivity it is claiming for Zocor 80 mg
Advertisement

Related Content

FDA Weighs Next Move After Appellate Court Rebuffs Patent Delisting Policy
FDA Weighs Next Move After Appellate Court Rebuffs Patent Delisting Policy
Ivax to join Zocor court battle
Ivax to join Zocor court battle
Pravachol Exclusivity Ruling Adds Uncertainty For ANDA Filers, Counsel Says
Generic Exclusivity Forfeiture Provisions Put FDA In “Hot Seat”
Biologic “Functional Equivalence” Being Considered By Insurers – WellPoint
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
180-Day Exclusivity Is An “Incentive,” Not A “Right,” FTC Says
180-Day Exclusivity Is An “Incentive,” Not A “Right,” FTC Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS046506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel